ERNA
Ernexa Therapeutics Inc.NASDAQHealthcare$0.20+4.59%ClosedMarket Cap: $1.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.69
P/S
0.00
EV/EBITDA
-0.03
DCF Value
$0.09
FCF Yield
-428.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1261.6%
ROA
-241.4%
ROIC
-316.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-2.1M | $-1.5M | $-0.19 | — |
| FY 2025 | $0.00 | -Infinity% | $-9.3M | $-14.1M | $-2.24 | — |
| Q3 2025 | $0.00 | NaN% | $-2.0M | $-1.2M | $-0.15 | — |
| Q2 2025 | $0.00 | NaN% | $-2.5M | $-3.1M | $-0.61 | — |
| Q1 2025 | $0.00 | NaN% | $-2.7M | $-8.2M | $-0.15 | — |
| Q4 2024 | $1.0K | 100.0% | $-2.7M | $-5.8M | $-0.42 | — |
| FY 2024 | $582.0K | 83.5% | $-15.7M | $-44.5M | $-1.57 | — |
| Q3 2024 | $487.0K | 112.3% | $-2.3M | $-26.6M | $-4.92 | — |
| Q2 2024 | $47.0K | -102.1% | $-4.9M | $-5.5M | $-1.02 | — |
| Q1 2024 | $47.0K | -1180.9% | $-5.8M | $-6.6M | $-1.23 | — |
| Q4 2023 | $17.0K | -288.2% | $-5.8M | $-6.2M | $-1.14 | — |
| FY 2023 | $68.0K | -247.1% | $-21.1M | $-21.7M | $-4.08 | — |